De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose
Hepatic de novo lipogenesis (DNL) is the biochemical process of synthesising fatty acids from acetyl‐CoA subunits that are produced from a number of different pathways within the cell, most commonly carbohydrate catabolism. In addition to glucose which most commonly supplies carbon units for DNL, fr...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Blackwell Publishing Ltd
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832395/ |
| id |
pubmed-4832395 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-48323952016-04-20 De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose Sanders, Francis W. B. Griffin, Julian L. Original Articles Hepatic de novo lipogenesis (DNL) is the biochemical process of synthesising fatty acids from acetyl‐CoA subunits that are produced from a number of different pathways within the cell, most commonly carbohydrate catabolism. In addition to glucose which most commonly supplies carbon units for DNL, fructose is also a profoundly lipogenic substrate that can drive DNL, important when considering the increasing use of fructose in corn syrup as a sweetener. In the context of disease, DNL is thought to contribute to the pathogenesis of non‐alcoholic fatty liver disease, a common condition often associated with the metabolic syndrome and consequent insulin resistance. Whether DNL plays a significant role in the pathogenesis of insulin resistance is yet to be fully elucidated, but it may be that the prevalent products of this synthetic process induce some aspect of hepatic insulin resistance. Blackwell Publishing Ltd 2015-03-04 2016-05 /pmc/articles/PMC4832395/ /pubmed/25740151 http://dx.doi.org/10.1111/brv.12178 Text en © 2015 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Sanders, Francis W. B. Griffin, Julian L. |
| spellingShingle |
Sanders, Francis W. B. Griffin, Julian L. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose |
| author_facet |
Sanders, Francis W. B. Griffin, Julian L. |
| author_sort |
Sanders, Francis W. B. |
| title |
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose |
| title_short |
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose |
| title_full |
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose |
| title_fullStr |
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose |
| title_full_unstemmed |
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose |
| title_sort |
de novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose |
| description |
Hepatic de novo lipogenesis (DNL) is the biochemical process of synthesising fatty acids from acetyl‐CoA subunits that are produced from a number of different pathways within the cell, most commonly carbohydrate catabolism. In addition to glucose which most commonly supplies carbon units for DNL, fructose is also a profoundly lipogenic substrate that can drive DNL, important when considering the increasing use of fructose in corn syrup as a sweetener. In the context of disease, DNL is thought to contribute to the pathogenesis of non‐alcoholic fatty liver disease, a common condition often associated with the metabolic syndrome and consequent insulin resistance. Whether DNL plays a significant role in the pathogenesis of insulin resistance is yet to be fully elucidated, but it may be that the prevalent products of this synthetic process induce some aspect of hepatic insulin resistance. |
| publisher |
Blackwell Publishing Ltd |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832395/ |
| _version_ |
1613566684426141696 |